(Q54539960)

31 May 2018

editorial

0 references

title

The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. (English)

1 reference

31 May 2018

1 reference

1

1 reference

31 May 2018

author name string

Chandrajit P Raut

series ordinal

2

1 reference

31 May 2018

publication date

1 April 2012

1 reference

31 May 2018

Annals of Surgical Oncology

published in

1 reference

31 May 2018

volume

19

1 reference

31 May 2018

issue

4

1 reference

31 May 2018

page(s)

1051-1055

1 reference

31 May 2018

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2191-4

10.1245/S10434-011-2191-4

21 January 2018

Identifiers

DOI

1 reference

31 May 2018

Dimensions Publication ID

1049223805

0 references

1 reference

31 May 2018